Study of Nimotuzumab in Combination With Neoadjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma

Inclusion Criteria:

• Histological or cytologic diagnosis of Esophageal squamous cell carcinoma
• ECOG performance status 0-2
• Age:18-70 years
• Joined the study voluntarily and signed informed consent form
• Patients must not have received any prior anticancer therapy
• Resectable disease, Stage IIA-IIIC, T2N0M0-T3N1M0（AJCC 2009）
• Target lesions can be measured according to RECIST criteria
• No serious system dysfunction and immuno-deficiency, Adequate organ function including the following: Hemoglobin ≥9 g/dL, WBC≥3x109/L, Neutrophils (ANC )≥1.5x109/L, platelet count ≥100x 109/L, TBIL<1.5 x ULN, ALT and AST ≦ 2.5 x ULN, creatinine ≦ 1.5 x ULN
• Use of an effective contraceptive for adults to prevent pregnancy
• Life expectancy of more than 3 months

Exclusion Criteria:

• Not suitable to surgery
• cervical Esophageal Carcinoma(distance of incisor tooth<19cm)
• early Esophageal Carcinoma(Stage I)
• complete esophageal obstruction，Esophageal perforation or hematemesis
• other malignant tumors, except for skin basal cell carcinoma, or cervical carcinoma in situ
• pregnant or breast-feeding women or people during the birth-period who refused to take contraceptives
• Uncontrolled seizures or psychiatric diseases, loss of control over their own behavior 11、 History of serious allergic or castor oil allergy 12、 Patients who are not suitable to participate in the trial according to researchers